Otherwise, pan-TRK IHC may be utilized on other locally advanced or metastatic non-GIST soft tissue tumors with are negative for known or diagnostic molecular alterations to screen for NTRK fusions; followed by NGS for positive of IHC equivocal results [53]. This evidence concerns the gene NTRK1 and gastrointestinal stromal tumor.